277 related articles for article (PubMed ID: 22566174)
1. Protein particulate detection issues in biotherapeutics development--current status.
Das TK
AAPS PharmSciTech; 2012 Jun; 13(2):732-46. PubMed ID: 22566174
[TBL] [Abstract][Full Text] [Related]
2. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
[TBL] [Abstract][Full Text] [Related]
3. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
[TBL] [Abstract][Full Text] [Related]
4. Issues and challenges of subvisible and submicron particulate analysis in protein solutions.
Scherer TM; Leung S; Owyang L; Shire SJ
AAPS J; 2012 Jun; 14(2):236-43. PubMed ID: 22391789
[TBL] [Abstract][Full Text] [Related]
5. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
[TBL] [Abstract][Full Text] [Related]
6. A critical review of methods for size characterization of non-particulate protein aggregates.
Philo JS
Curr Pharm Biotechnol; 2009 Jun; 10(4):359-72. PubMed ID: 19519411
[TBL] [Abstract][Full Text] [Related]
7. Separation and characterization of protein aggregates and particles by field flow fractionation.
Cao S; Pollastrini J; Jiang Y
Curr Pharm Biotechnol; 2009 Jun; 10(4):382-90. PubMed ID: 19519413
[TBL] [Abstract][Full Text] [Related]
8. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.
Helbig C; Ammann G; Menzen T; Friess W; Wuchner K; Hawe A
J Pharm Sci; 2020 Jan; 109(1):264-276. PubMed ID: 30914272
[TBL] [Abstract][Full Text] [Related]
9. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
Gervais D; Corn T; Downer A; Smith S; Jennings A
AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
[TBL] [Abstract][Full Text] [Related]
10. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
Zhang L; Shi S; Antochshuk V
J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
[TBL] [Abstract][Full Text] [Related]
11. Practical Considerations for Detection and Characterization of Sub-Micron Particles in Protein Solutions by Nanoparticle Tracking Analysis.
Gruia F; Parupudi A; Polozova A
PDA J Pharm Sci Technol; 2015; 69(3):427-39. PubMed ID: 26048748
[TBL] [Abstract][Full Text] [Related]
12. Multidimensional methods for the formulation of biopharmaceuticals and vaccines.
Maddux NR; Joshi SB; Volkin DB; Ralston JP; Middaugh CR
J Pharm Sci; 2011 Oct; 100(10):4171-97. PubMed ID: 21647886
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product.
Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P
J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460
[TBL] [Abstract][Full Text] [Related]
14. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
Tomlinson A; Demeule B; Lin B; Yadav S
Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
[TBL] [Abstract][Full Text] [Related]
15. Particles in therapeutic protein formulations, Part 1: overview of analytical methods.
Zölls S; Tantipolphan R; Wiggenhorn M; Winter G; Jiskoot W; Friess W; Hawe A
J Pharm Sci; 2012 Mar; 101(3):914-35. PubMed ID: 22161573
[TBL] [Abstract][Full Text] [Related]
16. Effects of surfaces and leachables on the stability of biopharmaceuticals.
Bee JS; Randolph TW; Carpenter JF; Bishop SM; Dimitrova MN
J Pharm Sci; 2011 Oct; 100(10):4158-70. PubMed ID: 21523787
[TBL] [Abstract][Full Text] [Related]
17. Recent Topics of Research in the Characterization and Quality Control of Biopharmaceuticals in Japan.
Ishii-Watabe A; Shibata H; Harazono A; Hyuga M; Kiyoshi M; Saitoh S; Iwura T; Torisu T; Goda Y; Uchiyama S
J Pharm Sci; 2017 Dec; 106(12):3431-3437. PubMed ID: 28802881
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effect of syringe surfaces on protein formulations.
Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
[TBL] [Abstract][Full Text] [Related]
19. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
[TBL] [Abstract][Full Text] [Related]
20. Electrohydrodynamic atomisation driven design and engineering of opportunistic particulate systems for applications in drug delivery, therapeutics and pharmaceutics.
Ali A; Zaman A; Sayed E; Evans D; Morgan S; Samwell C; Hall J; Arshad MS; Singh N; Qutachi O; Chang MW; Ahmad Z
Adv Drug Deliv Rev; 2021 Sep; 176():113788. PubMed ID: 33957180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
